The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose disposal rate () and hepatic glucose output (HGO) were a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2013/305347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550393685475328 |
|---|---|
| author | Kristina Wallenius Ann Kjellstedt Pia Thalén Lars Löfgren Nicholas D. Oakes |
| author_facet | Kristina Wallenius Ann Kjellstedt Pia Thalén Lars Löfgren Nicholas D. Oakes |
| author_sort | Kristina Wallenius |
| collection | DOAJ |
| description | Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose disposal rate () and hepatic glucose output (HGO) were assessed under basal fasting and hyperinsulinemic isoglycemic clamp conditions using [3,3H]glucose. Indices of tissue specific glucose utilization () were measured at basal, physiological, and supraphysiological levels of insulinemia using 2-deoxy-D-[2,6-3H]glucose. Finally, whole body and tissue specific FFA and glucose utilization and metabolic fate were evaluated under basal and hyperinsulinemic conditions using a combination of [U-13C]glucose, 2-deoxy-D-[U-14C]glucose, [U-14C]palmitate, and [9,10-3H]-(R)-bromopalmitate. Tesaglitazar improved whole body insulin action by greater suppression of HGO and stimulation of
compared to obese controls. This involved increased insulin stimulation of
in fat and skeletal muscle as well as increased glycogen synthesis. Tesaglitazar dramatically improved insulin mediated suppression of plasma FFA level, whole body turnover (), and muscle, liver, and fat utilization. At basal insulin levels, tesaglitazar failed to lower HGO or
compared to obese controls. In conclusion, the results demonstrate that tesaglitazar has a remarkable ability to improve insulin mediated control of glucose and FFA fluxes in obese Zucker rats. |
| format | Article |
| id | doaj-art-03c5c3693cd0466eb67c38b5f264b3f4 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-03c5c3693cd0466eb67c38b5f264b3f42025-02-03T06:06:46ZengWileyPPAR Research1687-47571687-47652013-01-01201310.1155/2013/305347305347The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker RatKristina Wallenius0Ann Kjellstedt1Pia Thalén2Lars Löfgren3Nicholas D. Oakes4AstraZeneca R&D Mölndal, 431 83 Mölndal, SwedenAstraZeneca R&D Mölndal, 431 83 Mölndal, SwedenAstraZeneca R&D Mölndal, 431 83 Mölndal, SwedenAstraZeneca R&D Mölndal, 431 83 Mölndal, SwedenAstraZeneca R&D Mölndal, 431 83 Mölndal, SwedenMetabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose disposal rate () and hepatic glucose output (HGO) were assessed under basal fasting and hyperinsulinemic isoglycemic clamp conditions using [3,3H]glucose. Indices of tissue specific glucose utilization () were measured at basal, physiological, and supraphysiological levels of insulinemia using 2-deoxy-D-[2,6-3H]glucose. Finally, whole body and tissue specific FFA and glucose utilization and metabolic fate were evaluated under basal and hyperinsulinemic conditions using a combination of [U-13C]glucose, 2-deoxy-D-[U-14C]glucose, [U-14C]palmitate, and [9,10-3H]-(R)-bromopalmitate. Tesaglitazar improved whole body insulin action by greater suppression of HGO and stimulation of compared to obese controls. This involved increased insulin stimulation of in fat and skeletal muscle as well as increased glycogen synthesis. Tesaglitazar dramatically improved insulin mediated suppression of plasma FFA level, whole body turnover (), and muscle, liver, and fat utilization. At basal insulin levels, tesaglitazar failed to lower HGO or compared to obese controls. In conclusion, the results demonstrate that tesaglitazar has a remarkable ability to improve insulin mediated control of glucose and FFA fluxes in obese Zucker rats.http://dx.doi.org/10.1155/2013/305347 |
| spellingShingle | Kristina Wallenius Ann Kjellstedt Pia Thalén Lars Löfgren Nicholas D. Oakes The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat PPAR Research |
| title | The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat |
| title_full | The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat |
| title_fullStr | The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat |
| title_full_unstemmed | The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat |
| title_short | The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat |
| title_sort | pparα γ agonist tesaglitazar improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the obese zucker rat |
| url | http://dx.doi.org/10.1155/2013/305347 |
| work_keys_str_mv | AT kristinawallenius thepparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT annkjellstedt thepparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT piathalen thepparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT larslofgren thepparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT nicholasdoakes thepparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT kristinawallenius pparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT annkjellstedt pparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT piathalen pparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT larslofgren pparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat AT nicholasdoakes pparagagonisttesaglitazarimprovesinsulinmediatedswitchingoftissueglucoseandfreefattyacidutilizationinvivointheobesezuckerrat |